Prostate cancer, BRCA-mutated

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 18:43, 2 May 2021 by Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Page editor''' ! col...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Page editor Section editor
LauraGraham.jpg
 Laura S. Graham, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA
Social-twitter-icon.png LauraGrahamMD
Alikhaki.jpg
 Ali Raza Khaki, MD
Stanford University
Palo Alto, CA
Social-twitter-icon.png arkhaki
7 regimens on this page
8 variants on this page

Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.


Metastatic castration-resistant

Rucaparib monotherapy

back to top

Regimen

Study Years of enrollment Evidence
(TRITON2) 2017-NR Phase II (RT)

Note: this study is the bases of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.

Targeted therapy

References

  1. TRITON2: NCT02952534
Retrieved from "https://hemonc.org/w/index.php?title=Prostate_cancer,_BRCA-mutated&oldid=49292"